The Strategic Imperative: Why European HCLS Should Look To The U.S. Now
In a global economy reshaped by innovation and evolving policy, European HCLS companies have a unique opportunity to accelerate growth by investing in the U.S. middle market. Our new thought leadership series—developed by CNM LLP, Cozen O’Connor, NOBLE Capital Markets, and Pathfinder Advisors LLC—dives into the strategic, operational, and financial reasons why the time to act is now.
🔹 Compressed U.S. valuations + innovation-rich sectors
🔹 Favorable budgetary, regulatory, and M&A conditions
🔹 Cross-border synergies driving sustainable global health outcomes
This first installment lays out the business case, key advantages, and regulatory shifts creating ripe conditions for transatlantic healthcare deals. Don’t miss these insights—and get ready for the July 24 webinar that takes the conversation further.